Rize Oncology Inc.
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -187.49% | -271.89% | -84.19% | 46.17% | -366.30% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.85% | 738.10% | 420.00% | -100.80% | 141.77% |
| Change in Net Operating Assets | 167.37% | 100.68% | -281.29% | 38.45% | -353.92% |
| Cash from Operations | -41.76% | -82.85% | -357.18% | -277.86% | -397.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 191.74% | 451.24% | 94.72% | -285.87% | 59.80% |
| Miscellaneous Cash Flow Adjustments | -354.44% | -- | -- | -- | -- |
| Net Change in Cash | -45.24% | -53.61% | -225.97% | 9,228.57% | -194.18% |